Fosun Pharma and Insilico Medicine partner for drug discovery and development using artificial intelligence
Fosun Pharma and Insilico Medicine will collaborate on AI-based drug discovery and product candidate development targeting multiple disease targets.
Shanghai Fosun Pharmaceutical (Fosun Pharma), a China-based healthcare group, and Insilico Medicine, a US-based artificial intelligence (AI) drug discovery and development company, announced on January 11, 2022 that they had entered into a collaborative agreement to advance the discovery and development of drugs targeting a number of different targets globally using AI technology.
The partnership includes an AI-focused research and development collaboration for drug discovery across four biological targets as well as the co-development of Insilico’s glutaminyl-peptide cyclotransferase (QPCTL)-like program. Under the agreement, Insilico will receive a total upfront payment of $13 million for the four collaborative R&D projects and co-development of the QPCTL program. Insilico will also receive potential milestone-based payments and share commercialization benefits from the QPCTL program. Fosun Pharma will also take a stake in Insilico.
Through this collaboration, Insilico will combine its end-to-end AI-based drug discovery platforms with the clinical development and commercial expertise of Fosun Pharma. Their goal is to discover and develop a portfolio of new therapies. Under the agreement, Insilico will take responsibility for delivering a preclinical candidate for the QPCTL program and advancing it to the Investigational New Drug (IND) stage (via its R&D team). After that, Fosun Pharma will conduct human clinical studies and co-develop the candidate globally. Fosun Pharma’s R&D team will also designate four therapeutic targets which will be evaluated by the AI platform and Insilico’s R&D team in parallel programs.
Additionally, as part of the collaboration, Fosun Pharma will have access to Insilico’s PandaOmics and Chemistry42 platforms to advance its own internal AI-powered discovery and development efforts.
“We are delighted to enter into a strategic collaboration with Insilico. Fosun Pharma is committed to promoting innovative R&D and moving towards addressing unmet clinical needs and improving product accessibility. We look forward to working with Insilico to leverage the technology and clinical development strengths of both companies, jointly improving the efficiency of innovative drug R&D and benefiting more patients around the world,” said Yifang Wu, Chairman- CEO of Fosun Pharma, in a company press release. .
“By partnering with Fosun Pharma, a leading pharmaceutical company, we are ushering in a new era of AI-powered end-to-end drug discovery and development, with human-machine collaboration becoming the new normal in drug discovery and development. the development of precision drugs. We have previously demonstrated that AI can be used to discover new targets and generate new molecules that can be tested in humans in record time. Now we are partnering with one of the leading scientific teams in the pharmaceutical industry to take this technology to the next level for the benefit of patients around the world,” said Alex Zhavoronkov, Founder and CEO of Insilico Medicine, in the Press release.
Source: Fosun Pharma